In esophageal cancer cells, PPARG activation by rosiglitazone led to suppressed proliferation and induced apoptosis through the inhibition of the Toll-like receptor 4 (TLR4)-dependent MAPK pathway [43]. The gene discussed is TLR4; the disease is esophageal cancer.